Who
Dillon JoEllen Lyons
Director
Company insider
Files Form 4 as: Director, Viatris; Director, World Wrestling Entertainmentinc; Director, Mylan II B.V; EVP, CLO & Corp Sec, ExOne Co; Director, Mylan.
In numbers
- Trades disclosed
- 100
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $247K
- Companies
- 5
- Companies where not an officer
- 4
- First trade
- 11 Mar 2013
- Last trade
- 6 Mar 2026
- Last filed
- 10 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 6 Mar 2026filed 10 Mar 2026 | VTRS ViatrisPharmaceuticals | SEC FORM 4 Code M | —23,660 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VTRS ViatrisPharmaceuticals | SEC FORM 4 Code M | —1,175 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VTRS Viatrisoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —23,660 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VTRS Viatrisoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —23,660 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VTRS Viatrisoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —1,174.49 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VTRS Viatrisoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —15,890 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VTRS Viatrisoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —1,174.492 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VTRS Viatrisoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —15,890 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VTRS ViatrisPharmaceuticals | SEC FORM 4 Code M | —23,660 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VTRS ViatrisPharmaceuticals | SEC FORM 4 Code M | —1,175 at $0.00 | filing |
| 6 Mar 2025filed 10 Mar 2025 | VTRS Viatrisoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —23,660 at $0.00 | filing |
| 4 Mar 2025filed 5 Mar 2025 | VTRS Viatrisoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —18,204 at $0.00 | filing |
| 4 Mar 2025filed 5 Mar 2025 | VTRS Viatrisoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —772.84 at $0.00 | filing |
| 4 Mar 2025filed 5 Mar 2025 | VTRS ViatrisPharmaceuticals | SEC FORM 4 Code M | —18,204 at $0.00 | filing |
| 4 Mar 2025filed 5 Mar 2025 | VTRS ViatrisPharmaceuticals | SEC FORM 4 Code M | —773 at $0.00 | filing |
| 5 Mar 2024filed 5 Mar 2024 | VTRS ViatrisPharmaceuticals | SEC FORM 4 Sold | $247K20,000 at $12.36 | filing |
| 4 Mar 2024filed 5 Mar 2024 | VTRS Viatrisoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —18,204 at $0.00 | filing |
| 3 Mar 2024filed 5 Mar 2024 | VTRS Viatrisoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —17,970 at $0.00 | filing |
| 3 Mar 2024filed 5 Mar 2024 | VTRS Viatrisoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —884.8 at $0.00 | filing |
| 3 Mar 2024filed 5 Mar 2024 | VTRS ViatrisPharmaceuticals | SEC FORM 4 Code M | —17,970 at $0.00 | filing |
News
Viatris' Dividend Has Room to Grow, but Will Management Deliver?VTRS · insidermonkey.com · 19 Oct 2026Viatris Receives U.S. FDA Approval for RYZUMVI® for the Treatment of PresbyopiaVTRS · prnewswire.com · 16 Oct 2026Could an FDA Nod for MR-141 Give Viatris (VTRS) and Opus Genetics (IRD) a Presbyopia Payoff?VTRS · insidermonkey.com · 9 Oct 2026
0 headlines in the last 90 days name Dillon JoEllen Lyons; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.
Sectors
Related people
Nobody else traded the same names lately.